De novo-designed transmembrane domains tune engineered receptor functions
journal contributionposted on 2022-06-03, 01:40 authored by A Elazar, NJ Chandler, AS Davey, JY Weinstein, JV Nguyen, R Trenker, RS Cross, Misty JenkinsMisty Jenkins, MJ Call, ME Call, SJ Fleishman
De novo-designed receptor transmembrane domains (TMDs) present opportunities for precise control of cellular receptor functions. We developed a de novo design strategy for generating programmed membrane proteins (proMPs): single-pass α-helical TMDs that self-assemble through computationally defined and crystallographically validated interfaces. We used these proMPs to program specific oligomeric interactions into a chimeric antigen receptor (CAR) that we expressed in mouse primary T cells and found that both in vitro CAR T cell cytokine release and in vivo antitumor activity scaled linearly with the oligomeric state encoded by the receptor TMD, from monomers up to tetramers. All programmed CARs stimulated substantially lower T cell cytokine release relative to the commonly used CD28 TMD, which we show elevated cytokine release through lateral recruitment of the endogenous T cell costimulatory receptor CD28. Precise design using orthogonal and modular TMDs thus provides a new way to program receptor structure and predictably tune activity for basic or applied synthetic biology.
PublishereLife Sciences Publications
Rights Statement© Copyright Elazar et al. This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/)., which permits unrestricted use and redistribution provided that the original author and source are credited.
Read the peer-reviewed publication
CAR T cellE. coliRosettachimeric antigen receptorde novo designimmunologyimmunotherapyinflammationmembrane proteinmolecular biophysicsmousestructural biologytransmembraneAnimalsCD28 AntigensCytokinesMiceProtein DomainsReceptors, Antigen, T-CellReceptors, Chimeric AntigenT-LymphocytesXenograft Model Antitumor Assays